FibroGen and Fortis sign exclusive licence deal for mCRPC drug candidate
09 May 2023
Phase 1License out/inADCAcquisition
Preview
Source: Pharmaceutical Technology
FOR46 is being developed as a potential treatment for metastatic castration-resistant prostate cancer. Credit: Nephron/commons.wikimedia.org
FibroGen has signed an exclusive licence agreement with Fortis Therapeutics for the FOR46 antibody-drug conjugate (ADC) that targets a new epitope on CD46, a protein-coding gene.
FOR46 is currently being investigated in a Phase I trial as a potential treatment for metastatic castration-resistant prostate cancer (mCRPC).
Recommended Reports
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - (Metyrapone + Oxazepam) in Substance (Drug) Abuse GlobalData
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Esmethadone Hydrochloride in Substance (Drug) Abuse GlobalData
View all
The trial is also studying the capability of FOR46 for use in other CD46-expressing cancersCD46-expressing cancers.
The new deal, which does not include any initial consideration, will see FibroGen conducting and financing new research, development and production of FOR46 and PET46.
Throughout the deal’s four-year evaluation period, FibroGen has an option to buy Fortis Therapeutics for $80m.
Fortis can also receive up to $200m in total on the basis of multiple regulatory approvals.
Under the clinical development strategy, FibroGen will continue the work of Fortis Therapeutics to develop a PET-based biomarker using a radiolabeled version of the targeting antibody (PET46) for selecting patients.
FibroGen CEO Enrique Conterno stated: “The agreement with Fortis Therapeutics bolsters FibroGen’s clinical pipeline in a capital-efficient manner, providing a product candidate with the potential to address a significant unmet medical need in oncology.
“FOR46 is a natural fit with our research and development capabilities and expertise.
“The flexibility of the agreement gives us the opportunity to clinically develop FOR46, and ultimately acquire it as a Phase III-ready asset, potentially delivering a therapy that may transform the treatment of patients with mCRPC and other CD46-expressing cancersCD46-expressing cancers.”
In early May 2023, FibroGen announced that it would receive a $150m non-dilutive term loan facility from funds managed by Morgan Stanley Tactical Value (MSTV) to accelerate the commercialisation of pamrevlumab.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.